Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine
The Lancet(1994)
Abstract
Natural interleukin-2 at low dose has been reported to overcome the non-responsiveness of patients with chronic uraemia to hepatitis B vaccine. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 μg of recombinant preS2–containing hepatitis B vaccine with human recombinat interleukin-2 (1 MU) or placebo (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 m/U/mL or more (56 vs 68%) were similar in both groups. Our rsults do not confirm local injection of interleukin-2 as an effective imunoadjuvant to hepatitis B vaccine in uraemic patients. Lancet 1994; 344: 856–57
MoreTranslated text
Key words
controlled trial
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined